Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taro Pharmaceuticals has received the go-ahead from the FDA to market generic equivalents of two creams for the treatment of inflammatory skin conditions. The two drugs are halobetasol propionate cream and hydrocortisone butyrate cream and are versions of Bristol-Myers Squibb and Ferndale Laboratories drugs, respectively.
Subscribe to our email newsletter
Halobetasol cream is a bioequivalent of Bristol-Myers Squibb’s Ultravate cream, a super-high potency prescription topical corticosteroid product used primarily for the treatment of inflammatory skin conditions.
According to industry sources, US sales of halobetasol cream products were approximately $24.7 million in 2004. Taro already markets an ointment version of this product.
Hydrocortisone butyrate cream is a generic version of Ferndale Laboratories’ Locoid cream. The approval of Taro’s abbreviated new drug application to market its version of this cream will give the company access to a US market for Locoid cream thought to be worth approximately $8.2 million in 2004.